188P Time until definitive deterioration (TUDD) in patient-reported outcomes (PROs) with ripretinib vs sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib who harbor KIT exon 11 + 17/18 mutations: Exploratory analysis from INTRIGUE